Insider Trades: These 5 ASX 200 insiders bought into recent share price weakness

Welcome back to the Insider Trades Series – A summary of on-market ASX 200 director transactions between 15-23 November, valued at more than $10,000.

Top ASX 200 Director Buys

All the above transactions are from Non-Executive Directors buying into recent share price weakness.

Ramsay Healthcare (ASX: RHC) shares are trading near nine-year lows. The company's FY23 results (24 August) flagged margin and profit pressures as inflationary pressures and higher interest costs weighed.

Ramsay Healthcare 12-month price chart (Source: Market Index)

Allkem (ASX: AKE) shares have almost halved since July. China's lithium carbonate spot prices fell for a 24th straight session on Wednesday to a fresh two-year low of 140,000 yuan a tonne.

Allkem 12-month price chart (Source: Market Index)

Xero (ASX: XRO) shares tumbled 12.4% on November 9 after its first-half result came in marginally below expectations. The company flagged slower-than-expected subscriber from in North America and the UK.

Xero 6-month price chart (Source: Market Index)

Top ASX 200 Director Sells

Pro Medicus (ASX: PME) founders Anthony Hall and Sam Hupert collectively sold $176 million on-market on Tuesday for one of the most bullish reasons I've ever seen. "The sale was in response to a strong approach from an individual fund and was done before market at the previous day’s closing price," the company said in a statement. Instead of selling off, the stock has remained relatively stable around all-time highs of $88 a share.

Pro Medicus 12-month price chart (Source: Market Index)

Lynas (ASX: LYC) CEO Amazon Lacaze was issued approximately $3 million worth of shares under the company's employee incentive scheme. Her sale of $7 million worth of shares marks the first insider sell since September 2022. Chinese NdPr prices remain near 3 year lows despite the recent bounce.

Source: Morgan Stanley